Company Overview
| Stock Name | Rainmed-B |
|---|---|
| Stock Code | 02297 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家中國醫療器械公司,專注於基於冠狀動脈造影的血流儲備分數系統(caFFR系統)及基於冠狀動脈造影的微血管阻力指數系統(caIMR系統)的設計、開發及商業化,核心產品用於評估冠狀動脈狹窄和微循環功能障礙引起的心肌缺血的嚴重程度。 |
| Listing Date | 2022-07-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 江蘇省蘇州市蘇州工業園區金雞湖大道99號東北區31棟 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.rainmed.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 6.24 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 6,240 |
| Par Value | To be extracted |
| Offer Period | 2022-06-27 to 2022-06-30 |
| Global Offering Shares | 23,348,000 shares |
| HK Public Offer Shares (Initial) | 2,336,000 shares (10.0%) |
| Public Offer Lots (Initial) | 2,336lots (Pool A1,168lots,Pool B1,168lots) |
| International Placing Shares (Initial) | 21,012,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,167,348,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 145,691,520 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 6,240 |
| 2 lots | 2,000 | HK$ 12,480 |
| 3 lots | 3,000 | HK$ 18,720 |
| 4 lots | 4,000 | HK$ 24,960 |
| 5 lots | 5,000 | HK$ 31,200 |
| 6 lots | 6,000 | HK$ 37,440 |
| 7 lots | 7,000 | HK$ 43,680 |
| 8 lots | 8,000 | HK$ 49,920 |
| 9 lots | 9,000 | HK$ 56,160 |
| 10 lots | 10,000 | HK$ 62,400 |
| 15 lots | 15,000 | HK$ 93,600 |
| 20 lots | 20,000 | HK$ 124,800 |
| 25 lots | 25,000 | HK$ 156,000 |
| 30 lots | 30,000 | HK$ 187,200 |
| 35 lots | 35,000 | HK$ 218,400 |
| 40 lots | 40,000 | HK$ 249,600 |
| 50 lots | 50,000 | HK$ 312,000 |
| 60 lots | 60,000 | HK$ 374,400 |
| 70 lots | 70,000 | HK$ 436,800 |
| 80 lots | 80,000 | HK$ 499,200 |
| 90 lots | 90,000 | HK$ 561,600 |
| 100 lots | 100,000 | HK$ 624,000 |
| 150 lots | 150,000 | HK$ 936,000 |
| 200 lots | 200,000 | HK$ 1,248,000 |
| 400 lots | 400,000 | HK$ 2,496,000 |
| 800 lots | 800,000 | HK$ 4,992,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 900 lots | 900,000 | HK$ 5,616,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 299.8M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +3140% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,284,251,520 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣633.6百萬元 |
| Period-End Cash Balance | 人民幣559.1百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 |
|---|---|---|
| Profit for the year | -145,240 | -633,646 |
Balance Sheet
| Item | 2020 | 2021 |
|---|---|---|
| Cash and cash equivalents | 27,588 | 559,140 |
| Inventories | 5,313 | 9,908 |
| Total current assets | 38,371 | 575,645 |
| Total assets | 70,522 | 640,192 |
| Total current liabilities | 52,985 | 44,067 |
| Total liabilities | 291,463 | 1,414,676 |
| Total equity | -220,941 | -774,484 |
| Equity attributable to owners | -220,933 | -774,484 |
| Interest-bearing borrowings | 11,020 | 0 |
Cash Flow Statement
| Item | 2020 | 2021 |
|---|---|---|
| Net cash from operating activities | 2,271 | -72,832 |
| Net cash from investing activities | 8,685 | -27,983 |
| Net cash from financing activities | 9,526 | 633,847 |
| Net increase in cash | 20,482 | 533,032 |
| Purchase of PP&E | -3,998 | -30,835 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 5.28 |
|---|---|
| First Day Open | HK$ 5.6 |
| First Day Change | -15.38% |
| First Day Volume | 5633000.0 |
| First Day Turnover | 32209800.0 |
| Use of Proceeds | 1、80.0%或約63.1百萬港元將撥作我們的核心產品caFFR系統及caIMR系統;
2、16.5%或約13.2百萬港元將撥作其他管線產品的持續研發、生產及商業化的資金;
3、3.5%或約2.7百萬港元將撥作一般營運資金及一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (4)
Joint Lead Managers (5)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 霍雲飛 | — |
| Company Secretary | 張亮、朱卓婷 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 霍雲飛先生透過Opera Rose Limited等持有約18.66%,霍雲龍博士透過Vermilion Bird Limited持有約13.70%,平安集團持有約10.28%,同襄灝乾及同創偉業集團合共持有約11.10%,周彬先生持有約7.09%,河北東拓投資有限公司持有約5.12%,上海景邁潤持有約5.05%。 |
|---|




